Physiologically Based Pharmacokinetic Modeling to Simulate CYP3A4-Mediated Drug-Drug Interactions for Pyrotinib

Area of Science:

• Pharmacology
• Drug Metabolism
• Computational Modeling

Background:

• Pyrotinib, a tyrosine kinase inhibitor, undergoes significant metabolism via cytochrome P450 3A4 (CYP3A4).
• Understanding drug interactions with CYP3A4 perpetrators is crucial for safe pyrotinib use during clinical trials.

Purpose of the Study:

• To develop and validate a physiologically based pharmacokinetic (PBPK) model for pyrotinib.
• To predict the impact of CYP3A4 perpetrators on pyrotinib exposure using PBPK modeling.

Main Methods:

• A PBPK model for pyrotinib was constructed using PK-Sim®.
• Model parameters were optimized using clinical pharmacokinetic data and validated against observed data.
• Simulations were performed with known CYP3A4 perpetrator drug interaction models.

Main Results:

• The PBPK model accurately predicted pyrotinib pharmacokinetics in single and multiple doses.
• Simulations indicated a substantial increase in pyrotinib exposure (over sixfold) with potent CYP3A4 inhibitors like itraconazole.
• The interaction with rifampicin was underestimated, while weak CYP3A4 inhibitors showed minimal effects.

Conclusions:

• PBPK modeling effectively predicts significant drug-drug interactions for pyrotinib.
• Avoidance of coadministration with potent CYP3A4 perpetrators is recommended to prevent excessive pyrotinib exposure.
• This modeling approach aids in preventing irrational medication choices in pyrotinib chemotherapy regimens.